Spots Global Cancer Trial Database for Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
Official Title: Study of Anlotinib Single Drug as the Maintenance Treatment for Advanced Non-Small Cell Lung Cancer （NSCLC）
Study ID: NCT03998085
Conditions
Interventions
Study Description
Brief Summary: Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of anlotinib in maintenance therapy for advanced NSCLC to prospectively evaluate the efficacy of anlotinib in maintenance therapy for advanced NSCLC. Value, to provide a scientific basis for prolonging the survival time of patients with advanced NSCLC, improving the quality of life of patients in the course of treatment, and optimizing treatment strategies to a greater extent.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
First Hospital of Jilin University, Chang chun, Jilin, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
